Genenta Science products

After apheresis collection, a functional copy of the therapeutic gene is inserted into the patient’s own HSPCs using a non-replicating lentiviral vector. This is an ex-vivo process called transduction. We believe that LVVs are the first choice for ex-vivo gene therapy in humans because they can efficiently transduce HSPCs with potentially large transgenes that will allow us to expand therapeutic options to a multitude of payloads. Most importantly, there is an abundance of safety data generated using these vectors to develop novel medicines currently in clinical development.

Temferon™ is a lenti-virus based hematopoietic stem progenitor cell immuno-gene therapy enabling controlled and targeted interferon-α expression within cancers. Biologically delivered via engineered tumor infiltrating monocytes (Tie2 expressing monocytes – TEMs), Temferon™ generates immune responses to any TEMs positive tumors. As such the biological readouts and safety of Temferon™ in Glioblastoma patients should support the potential development of Temferon across a broad range of solid tumors that recruit TEMs. Underlying Temferon™ is a platform technology that controls the expression of the gene within the tumor microenvironment and can be applied to multiple different payloads. As a gene therapy, the impact is enduring, creating potentially life-long tumor surveillance.